Solabegron
CAS: 252920-94-8
Ref. 3D-CKA92094
| 1mg | A consultar | ||
| 2mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Informação sobre produto
- (-)-(R)-3′-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]biphenyl-3-carboxylic acid
- 3′-[[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino][1,1′-biphenyl]-3-carboxylic acid
- Gw 427353
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-
Solabegron is a drug that has clinical relevance for the treatment of bladder disorders. It is an agonist of the beta-3 adrenergic receptor, with no affinity for beta-1 or beta-2 receptors. In animal models, solabegron has been shown to increase detrusor muscle contractility and reduce urinary symptoms. Solabegron also acts as an inhibitor of DPP-IV, which is involved in the breakdown of glucagon-like peptide (GLP). The drug reduces body mass index and improves metabolic disorders in animals by stimulating GLP secretion. Solabegron is metabolized by CYP3A4 and has hydrogen bonding interactions with drugs such as erythromycin, clarithromycin, and telithromycin.
Propriedades químicas
Consulta técnica sobre: 3D-CKA92094 Solabegron
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
